Helicobacter pylori lipopolysaccharide inhibition of gastric somatostatin receptor: effect of sucralfate.
In this study, we investigated the inhibitory effect of Helicobacter pylori lipopolysaccharide on the binding of somatostatin to gastric epithelial cell membrane receptor, and assessed the effect of antiulcer agent, sucralfate, on this process. The assays conducted with the somatostatin receptor, purified from the solubilized epithelial cell membranes by affinity chromatography on Affi-Gel-[D-Tryp8]SRIF-14, revealed a dose-dependent inhibition in receptor-somatostatin binding by the lipopolysaccharide which reached a maximum of 94.1%. This effect of H. pylori lipopolysaccharide was countered by sucralfate that produced a 92.5% restoration in receptor-somatostatin binding at 70 micrograms/ml of the drug. The findings demonstrate that sucralfate is capable of reversing the interference by H. pylori lipopolysaccharide with somatostatin-receptor binding on gastric mucosal G-cells.
Piotrowski
J
J
Research Center, University of Medicine and Dentistry of New Jersey, Newark 07103-2400, USA.
Slomiany
A
A
Slomiany
B L
BL
D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002846:Chromatography, Affinity; D004305:Dose-Response Relationship, Drug; D005246:Feedback; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005755:Gastrins / Q000378:metabolism; D016480:Helicobacter pylori / Q000737:chemistry / Q000502:physiology*; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017481:Receptors, Somatostatin / Q000187:drug effects* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives / Q000378:metabolism; D013392:Sucralfate / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D005755:Gastrins; D008070:Lipopolysaccharides; D017481:Receptors, Somatostatin; D013004:Somatostatin; D013392:Sucralfate; C017783:somatostatin, Trp(8)-